Heart failure & cardiomyopathies

Four Decades of Heart–Lung Transplantation: Milestones and Outcomes in Advanced Cardiorespiratory Failure

ESC Heart FailPublished single-centre retrospective cohort study

Authors' conclusion

HLTx outcomes at our centre are consistent with international benchmarks. Survival has improved in Era 2, likely due to individualised immunosuppressive regimens, novel organ preservation techniques and enhanced surveillance. These results support ongoing optimisation of multidisciplinary care for complex cardiopulmonary failure.

Study context

Population
Patients with severe cardiorespiratory failure who underwent heart-lung transplantation (HLTx), with follow-up through June 2024patients who underwent HLTx between 1983–1995 (Era 1) and 1996–2010 (Era 2)
Participants
80 patients
Exposure
Survival in Era 1 vs Era 2
Outcome
All-cause mortality (survival)
Follow-up
1, 5 and 10 years post-transplant

Main finding

As reported in the abstract

Group1 year5 years10 years
Era 146 ± 10%18 ± 9%9 ± 6%
Era 266 ± 7%5 ± 7%45 ± 7%

1 year

Era 146 ± 10%
Era 266 ± 7%

5 years

Era 118 ± 9%
Era 25 ± 7%

10 years

Era 19 ± 6%
Era 245 ± 7%
Overall survival at 1 year
60 ± 6%
Overall survival at 5 years
46 ± 6%
Overall survival at 10 years
35 ± 6%

Observational data: associations, not effects.

Secondary outcomes

Risks for mortality

ComparisonOR (95% CI)P value
Heart failure4.557 (1.057–19.648)P = 0.042
Gastrointestinal bleeding2.739 (1.310–5.726)P = 0.016
  • Risks for mortality: These factors remained significant in multivariable analysis.

Univariable risk factors for increased mortality

Euro Collins versus Perfadex lung preservation
P < 0.001
University of Wisconsin (UW2) versus Histidine-Tryptophan-Ketoglutarate (HTK) solution cardioplegia
P < 0.001
Epstein-Barr virus infection
P = 0.036

Original publication

Four Decades of Heart–Lung Transplantation: Milestones and Outcomes in Advanced Cardiorespiratory Failure. ESC Heart Fail. Published 27 August 2025. doi:10.1002/ehf2.15411

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.